Xilio Therapeutics, Inc. (XLO) ownership: Top institutional holder: GILEAD SCIENCES, INC. ($5.47M). Insider activity: Net Seller (0 buys, 3 sells). SEC EDGAR first-party data.
| Holder | Shares | Market Value | Reported |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 650389.00 | $5.47M | 2026-03-31 |
| Bain Capital Life Sciences Investors, LLC | 7372686.00 | $4.72M | 2025-12-31 |
| Frazier Life Sciences Management, L.P. | 5915091.00 | $3.79M | 2025-12-31 |
| Point72 Asset Management, L.P. | 4000000.00 | $2.56M | 2025-12-31 |
| Sio Capital Management, LLC | 2134537.00 | $1.37M | 2025-12-31 |
| Merck & Co., Inc. | 1483758.00 | $949902.00 | 2025-12-31 |
| VANGUARD GROUP INC | 1255692.00 | $803643.00 | 2025-12-31 |
| Empery Asset Management, LP | 1183040.00 | $757382.00 | 2025-12-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-04-15 | |
| Sell | null | 2026-03-26 | |
| Sell | null | 2026-02-13 |
Back to XLO overview · XLO earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.